Cargando…

Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity

Triple-negative breast cancers (TNBCs) display great diversity in cisplatin sensitivity that cannot be explained solely by cancer-associated DNA repair defects. Differential activation of the DNA damage response (DDR) to cisplatin has been proposed to underlie the observed differential sensitivity,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heijink, Anne Margriet, Everts, Marieke, Honeywell, Megan E., Richards, Ryan, Kok, Yannick P., de Vries, Elisabeth G.E., Lee, Michael J., van Vugt, Marcel A.T.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cell Press 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718811/ https://www.ncbi.nlm.nih.gov/pubmed/31461651 http://dx.doi.org/10.1016/j.celrep.2019.07.070

Ejemplares similares

An mRNA expression-based signature for oncogene-induced replication-stress
por: Llobet, Sergi Guerrero, et al.
Publicado: (2022)

Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors
por: Kok, Yannick P., et al.
Publicado: (2020)

Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer
por: Guerrero Llobet, Sergi, et al.
Publicado: (2020)

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
por: Heijink, Anne Margriet, et al.
Publicado: (2019)

Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine
por: Pool, Martin, et al.
Publicado: (2017)

Shutting down the power supply for DNA repair in cancer cells
por: van Vugt, Marcel A.T.M.
Publicado: (2017)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells
por: van Gijn, Stephanie E., et al.
Publicado: (2018)

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity
por: Wadhwa, Bhumika, et al.
Publicado: (2020)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

FLICK: an optimized plate reader-based assay to infer cell death kinetics
por: Richards, Ryan, et al.
Publicado: (2021)

Inflammatory signaling in genomically instable cancers
por: Talens, Francien, et al.
Publicado: (2019)

Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51
por: Heijink, Anne Margriet, et al.
Publicado: (2022)

ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells
por: Zhang, Yang, et al.
Publicado: (2018)

Urtica dioica Leaf Infusion Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Cisplatin Treatment
por: Nafeh, Guy, et al.
Publicado: (2023)

Never tear us a-PARP: Dealing with DNA lesions during mitosis
por: Schoonen, Pepijn M., et al.
Publicado: (2017)

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
por: Hill, David P., et al.
Publicado: (2019)

Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models
por: Balza, Enrica, et al.
Publicado: (2021)

Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT
por: Jin, Yujin, et al.
Publicado: (2019)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer
por: Fedoseienko, Alina, et al.
Publicado: (2016)

miR-638 mediated regulation of BRCA1affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer
por: Tan, Xiaohui, et al.
Publicado: (2014)

Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
por: Hettinga, J. V., et al.
Publicado: (1997)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells
por: Li, Shujun, et al.
Publicado: (2020)

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
por: Martens-de Kemp, Sanne R., et al.
Publicado: (2013)

Tumor‐stroma interactions differentially alter drug sensitivity based on the origin of stromal cells
por: Landry, Benjamin D, et al.
Publicado: (2018)

Cisplatin Loaded Multiwalled Carbon Nanotubes Induce Resistance in Triple Negative Breast Cancer Cells
por: Badea, Madalina Andreea, et al.
Publicado: (2018)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
por: Salerno, Dominick, et al.
Publicado: (2021)

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
por: Telli, Melinda L., et al.
Publicado: (2022)

Synergistic effects of combined cisplatin and Clinacanthus nutans extract on triple negative breast cancer cells
por: Abu Bakar, Nur Fitriyani Afiqah Binti, et al.
Publicado: (2023)

Processing DNA lesions during mitosis to prevent genomic instability
por: Audrey, Anastasia, et al.
Publicado: (2022)

Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines
por: Busch, Chia-Jung, et al.
Publicado: (2016)

Drug GRADE: An Integrated Analysis of Population Growth and Cell Death Reveals Drug-Specific and Cancer Subtype-Specific Response Profiles
por: Schwartz, Hannah R., et al.
Publicado: (2020)

Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer
por: C, Ahammad Sameer, et al.
Publicado: (2023)

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
por: Huang, Yajing, et al.
Publicado: (2020)

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
por: Lee, Jung Ok, et al.
Publicado: (2019)

Quantitative proteomic analysis of enhanced cellular effects of electrochemotherapy with Cisplatin in triple-negative breast cancer cells
por: Mittal, Lakshya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lbagghgjmtje429nqh25ojg4j6